Mount Sinai Clinical Experience with Leucovorin and 5-Fluorouracil

  • Howard W. Bruckner
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 131)


The early Mount Sinai clinical experience appears to be relevant to unresolved questions concerning both leucovorin (LV) dosage and 5-fluorouracil (FU) schedules examined in the Gastrointestinal Tumor Study Group (GITSG) and Mayo Clinic-North Central trials. In addition, recent findings in the course of evolving practice provide support for specific new applications of LV-FU for combined modality and combination chemotherapy.


Gastric Cancer Pancreatic Cancer Bolus Regimen Gastrointestinal Tumor Study Group Peripheral Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    H. W. Bruckner, J. A. Storch, and J. F. Holland, Leucovorin increases the toxicity of 5-fluorouracil: phase I clinical pharmacological trials, Proc Am Assoc Cancer Res, 22: 192 (1981).Google Scholar
  2. 2.
    H. W. Bruckner, J. Roboz, M. Spigelman, E. Ambinder, R. Hart, and J. F. Holland, An efficient leucovorin-5fluorouracil sequence: dosage escalation and pharmacologic monitoring, in: “Advances in cancer chemotherapy. The current status of 5-fluorouracil-leucovorin calcium combination,” H. W. Bruckner, J. Rustum, eds., Park Row Publishers, New York (1984)Google Scholar
  3. 3.
    H. W. Bruckner and M. K. Spigelman. Leucovorin as a clinical potentiator of 5-fluorouracil. Toxicity and anticancer efficacy, Mount Sinai J Med (1988). In PressGoogle Scholar
  4. 4.
    H. W. Bruckner, Crown, A. McKenna, and R. Hart, 5-J. Leucovorin fluorouracil as a treatment for and minated disse-of the pancreas and unknown cancer tumors, primary, Cancer Res (1988). In PressGoogle Scholar
  5. 5.
    H. W. Bruckner, J. Cohen, MTX/5-FU trials in gastrointestinal and other cancers, Sem Oncol, 10: 32 (1983).Google Scholar
  6. 6.
    H. W. Bruckner, and D. M. Stablein for the Gastrointestinal Tumor Study Group, A randomized study of 5fluorouracil and doxorubicin with semustine, cis-platin, or triazinate for treatment of advanced gastric cancer. Proc Am Soc Clin Oncol, 5: 90 (1986).Google Scholar
  7. 7.
    H. W. Bruckner, Gastric cancer trials: implications of the gastrointestinal tumor study group and the Mount Sinai Medical Center experience, in: Gastric Carcinoma Workshop, Utopia Medical Publications, Inc., New Isenburg, (1988), In PressGoogle Scholar
  8. 8.
    D. V. Santi, A biochemical rationale for the use of 5-FU in combination with leucovorin, In: Advances in cancer chemotherapy: the current status of 5-FU-leucovorin calcium combination, H. W. Bruckner and Y. M. Rustum, eds., Park Row Publishers, Inc., New York (1984)Google Scholar
  9. 9.
    H. W. Bruckner, M. Rubinoff, and S. Waxman, Limited effectiveness of in vitro high-dose methotrexate and leucovorin to overcome resistance in L1210 leukemia cells with elevations of dihydrofolate reductase, Euroo. J Cancer, 16: 1057 (1980).CrossRefGoogle Scholar
  10. 10.
    R. G. Moran, P. V. Danenberg, and C. Heidelberger C, Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis, Bioch Pharmacol, 31: 2929 (1982)CrossRefGoogle Scholar
  11. 11.
    H. W. Bruckner, R. Hart, M. Spigelman, E. Feuer, J. F. and Holland, An intermittent leucovorin-5-fluorouracil regimen for advanced adenocarcinoma of the colon, Proc Am Assoc Cancer Res, 28: 202 (1987)Google Scholar
  12. 12.
    H. W. Bruckner, N. J. Petrelli, D. Stablein, R. Mayer, J. Novak, and the Gastrointestinal Tumor Study Group, Comparison of unique leucovorin and “maximum” dosage strategies. Natl Cancer Inst Monqr, 5: 179 (1987)Google Scholar
  13. 13.
    N. Petrelli, D. Stablein, H. Bruckner, A. Megibow, R. Mayer and H. Douglass, A prospective randomized phase III trial of 5-fluorouracil (5FU) versus 5FU + high-dose leucovorin versus 5-FU + low-dose leucovorin in patients with metastatic colorectal adenocarcinomas. Proc Am Soc Clin Oncol, 7: 94 (1988).Google Scholar
  14. 14.
    P. Preusser, H. Wilke, W. Achterrath, U. Fink, J. Meyer, U. Schmitz-Hubner, and H. Bunte, Advanced gastric carcinoma: a phase II study with etoposide, adriamycin and split course cisplatin (EAP), Proc Am Soc Clin Oncol 6: 75 (1987)Google Scholar
  15. 15.
    J. Wils, H. Bleiberg, O. Dalesio, G. Blijham, N. Mulder, A. Planting, T. Splinter, and N. Duez, An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer, J Clin Oncol, 4: 1799 (1986).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Howard W. Bruckner
    • 1
  1. 1.Mount Sinai School of MedicineNew YorkUSA

Personalised recommendations